本研究的目的是评价重组人内皮抑素联合长春瑞滨  顺铂（NPE）治疗晚期非小细胞肺癌（NSCLC）的有效性和安全性。NPE治疗晚期NSCLC的随机对照试验（RCT）使用计算机检索数据库，检索自创建之时至 2023 年 5 月的 PubMed、Cochrane Library、EMBASE、Web of Science、中国知识基础设施和万方数据库中的文献信息。两名研究者独立提取文献信息并评估文献质量包括文献。采用RevMan 5.4.0软件进行Meta分析，最终纳入24个RCT，2114例晚期NSCLC患者。 Meta分析结果显示，接受NPE方案组的总有效率显着高于未接受NPE方案组（RR = 1.70，95% CI：1.48~1.95，P < .00001）。同时，接受NPE方案组的临床获益率也显着高于未接受NPE方案组（RR = 1.22，95% CI：1.15~1.29，P < .00001）。但两组不良事件发生率差异无统计学意义（RR = 0.98，95% CI：0.76-1.27，P = .88）。与NP（长春瑞滨  顺铂）方案治疗晚期NSCLC患者相比，NPE方案提高了治疗的总有效率和临床获益率，但不良反应不可能有显着差异。需要进行前瞻性随机试验来进一步验证这种治疗方式的安全性和有效性。作者版权所有 © 2024。由 Wolters Kluwer Health, Inc. 出版

The aim of this study was to evaluate the efficacy and safety of recombinant human endostatin in combination with vinorelbine + cisplatin (NPE) for the treatment of advanced non-small cell lung cancer (NSCLC).Randomized controlled trials (RCTs) of NPE for advanced NSCLC in PubMed, Cochrane Library, EMBASE, Web of Science, China National Knowledge Infrastructure, and Wanfang databases were searched using a computerized search of the database from the time of creation to May 2023. Two investigators independently extracted literature information and assessed the quality of the included literature. Meta-analysis was performed using RevMan 5.4.0 software.A total of 24 RCTs with 2114 patients with advanced NSCLC were finally included. The results of meta-analysis showed that the total effective rate in the group received NPE regimen was significantly higher than those in the group without NPE regimen (RR = 1.70, 95% CI: 1.48-1.95, P < .00001). Meanwhile, the clinical benefit rate in the group received NPE regimen was also significantly higher than those in the group without NPE regimen (RR = 1.22, 95% CI: 1.15-1.29, P < .00001). However, there was no significant difference in the incidence of adverse event rate between the 2 groups (RR = 0.98, 95% CI: 0.76-1.27, P = .88).Compared with NP (vinorelbine + cisplatin) regimens for patients with advanced NSCLC, NPE regimens improve the total effective rate and clinical benefit rate of treatment, but there can be no significant difference in adverse effects. Prospective randomized trials are needed to further validate the safety and efficacy of this treatment modality.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.